Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Archives of Dermatology

• Publication date

  2006-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHDERM.142.5.555PMID 16702492
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.

  2005cited by this paper
• Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.

  2005cited by this paper
• The performance of SolarScan: an automated dermoscopy image analysis instrument for the diagnosis of primary melanoma.

  2005cited by this paper
• A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.

  2003cited by this paper
• New concepts in the pathogenesis of atopic dermatitis.

  2003cited by this paper
• Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

  2003cited by this paper
• Cyclosporine in atopic dermatitis. Modulation in the expression of immunologic markers in lesional skin.

  1992cited by this paper

• T cell co-stimulatory and co-inhibitory pathways in atopic dermatitis

  2023cites this paper
• Biologics for the Treatment of Atopic Dermatitis

  2018cites this paper
• Monoclonal Antibodies for Atopic Dermatitis: Progress and Potential

  2017cites this paper
• Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines.

  2017cites this paper
• Past, present, and future for biologic intervention in atopic dermatitis

  2015cites this paper
• Systemic therapy of childhood atopic dermatitis.

  2015cites this paper
• Biological Treatments in Atopic Dermatitis

  2015cites this paper
• Biologics in Dermatology: An Integrated Review

  2014cites this paper
• Systemic Therapy of Atopic Dermatitis in Children

  2012cites this paper
• Advances in management of atopic dermatitis: new therapies and novel uses of existing treatments.

  2012cites this paper
• Safe and Effective Medicines for Children

  2012cites this paper
• Systemic Therapies in Pediatric Atopic Dermatitis

  2011cites this paper
• Efalizumab

  2011cites this paper
• Nuevas perspectivas terapéuticas en dermatitis atópica Atopic dermatitis. New therapies for the future

  2011cites this paper
• T Cell Inhibitors for the Treatment of Psoriasis

  2011cites this paper
• Atopic dermatitis: epidemiology & off-label therapy

  2011cites this paper
• UTILIZAÇÃO OFF-LABEL DE TERAPÊUTICA BIOLÓGICA EM DERMATOLOGIA – EXPERIÊNCIA CLÍNICA DE 5 ANOS

  2011cites this paper
• Off-label use of efalizumab in dermatology

  2010cites this paper
• Eosinphils increase sensory neuron branching

  2010cites this paper
• 24. Atopic Dermatitis

  2010cites this paper
• Interleukin‐1 from epithelial cells fosters T cell‐dependent skin inflammation

  2010cites this paper
• Use of biologic agents in pediatric psoriasis.

  2010cites this paper
• Off-label use of efalizumab

  2010cites this paper
• Systemic therapeutic options for severe atopic dermatitis

  2009cites this paper
• Immunosuppressants as Treatment for Atopic Dermatitis

  2009cites this paper
• Update on the Management of Atopic Dermatitis/Eczema

  2009cites this paper
• Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

  2009cites this paper
• Alopecia areata treated with efalizumab: a case with significant hair re-growth after long-term therapy.

  2009cites this paper
• Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights.

  2008cites this paper
• of atopic dermatitis

  2008cites this paper
• Novel immunological approaches in the treatment of atopic eczema

  2008cites this paper
• [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab].

  2008cites this paper
• Are Biologics Safe in the Treatment of Atopic Dermatitis? A Review with a Focus on Immediate Hypersensitivity Reactions

  2008cites this paper
• [Review and update of current understanding of childhood atopic dermatitis].

  2008cites this paper
• Anti‐lymphocyte function associated antigen‐1 inhibits T‐helper 2 function of human allergen‐specific CD4+ T cells

  2008cites this paper
• Alefacept for moderate to severe atopic dermatitis: a pilot study in adults.

  2008cites this paper
• Cutaneous adverse effects of biological therapies for psoriasis.

  2008cites this paper
• Dermatitis atópica infantil: revisión y actualización

  2008cites this paper
• Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Segunda parte: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab

  2008cites this paper
• Experimental therapeutic strategies for thetreatment of atopic dermatitis

  2008cites this paper
• Exacerbation of Pityriasis Rubra Pilaris under Efalizumab Therapy

  2007cites this paper
• Rebound vasodilation from long-term topical corticosteroid use.

  2007cites this paper
• Use of biological agents in patients with moderate to severe psoriasis: a cohort-based perspective.

  2007cites this paper
• Efalizumab in the treatment of discoid lupus erythematosus.

  2007cites this paper
• Complications and adverse reactions in the use of newer biologic agents.

  2007cites this paper
• Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).

  2007cites this paper
• Antipsoriatic biologic agents for the treatment of atopic dermatitis.

  2007cites this paper
• Immunsuppressiva und Biologics bei Kindern

  2007cites this paper
• Immuntherapie der atopischen Dermatitis

  2007cites this paper
• Topo-Proteomic in situ Analysis of Psoriatic Plaque under Efalizumab Treatment

  2007cites this paper
• Combination immunosuppressive therapies: the promise and the peril.

  2007cites this paper
• Efalizumab

  2007cites this paper
• Méthode de détection d'un motif d'exemple moléculaire combinable, spécifique à La maladie dans un échantillon de tissu d'un patient

  2006cites this paper